CAR T Cell Immunotherapy Beyond Haematological Malignancy

키워드

참고문헌 (110)

1. June CH, "Adoptive cellular therapy : a race to the finish line", Sci Transl Med, 7, pp.280~ (2015)
2. Sadelain M, "The basic principles of chimeric antigen receptor design", Cancer Discov, 3, pp.388~398 (2013)
3. Tokarew N, "Teaching an old dog new tricks : nextgeneration CAR T cells", Br J Cancer, 120, pp.26~37 (2019)
4. Finney HM, "Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product", J Immunol, 161, pp.2791~2797 (1998)
5. Maher J, "Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta", CD28 receptor, 2002, pp.20, 70~75
6. Imai C, "Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia", Leukemia, 18, pp.676~684 (2004)
7. Maude SL, "Chimeric antigen receptor T cells for sustained remissions in leukemia", N Engl J Med, 371, pp.1507~1517 (2014)
8. Ali SA, "T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma", Blood, 128, pp.1688~1700 (2016)
9. Valkenburg KC, "Targeting the tumour stroma to improve cancer therapy", Nat Rev Clin Oncol, 15, pp.366~381 (2018)
10. Wherry EJ, "T cell exhaustion", Nat Immunol, 12, pp.492~499 (2011)
11. Maldini CR, "CAR T cells for infection, autoimmunity and allotransplantation", Nat Rev Immunol, 18, pp.605~616 (2018)
12. Majzner RG, "Tumor antigen escape from CAR T-cell therapy", Cancer Discov, 8, pp.1219~1226 (2018)
13. Rafiq S, "Tumors evading CARs-the chase is on", Nat Med, 24, pp.1492~1493 (2018)
14. O’Rourke DM, "A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma", Sci Transl Med, 9, pp.eaaa0984~ (2017)
15. Rafiq S, "Engineering strategies to overcome the current roadblocks in CAR T cell therapy", Nat Rev Clin Oncol, 17, pp.147~167 (2020)
16. Fry TJ, "CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy", Nat Med, 24, pp.20~28 (2018)
17. Pan J, "CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia", Leukemia, 33, pp.2854~2866 (2019)
18. Shah NN, "Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies : a phase 1dose escalation and expansion trial", Nat Med, 26, pp.1569~1575 (2020)
19. Spiegel JY, "CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies : a phase 1 trial", Nat Med, 27, pp.1419~1431 (2021)
20. Goebeler ME, "T cell-engaging therapies-BiTEs and beyond", Nat Rev Clin Oncol, 17, pp.418~434 (2020)
21. Choi BD, "CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity", Nat Biotechnol, 37, pp.1049~1058 (2019)
22. Kudo K, "T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing", Cancer Res, 74, pp.93~103 (2014)
23. Urbanska K, "A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor", Cancer Res, 72, pp.1844~1852 (2012)
24. Tamada K, "Redirecting gene-modified T cells toward various cancer types using tagged antibodies", Clin Cancer Res, 18, pp.6436~6445 (2012)
25. Ma JS, "Versatile strategy for controlling the specificity and activity of engineered T cells", Proc Natl Acad Sci U S A, 113, pp.E450~E458 (2016)
26. Rodgers DT, "Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies", Proc Natl Acad Sci U S A, 113, pp.E459~E468 (2016)
27. Cho JH, "Universal chimeric antigen receptors for multiplexed and logical control of T cell responses", Cell, 173, pp.1426~1438 (2018)
28. Cho JH, "Engineering advanced logic and distributed computing in human CAR immune cells", Nat Commun, 12, pp.792~ (2021)
29. Kim MS, "Redirection of genetically engineered CAR-T cells using bifunctional small molecules", J Am Chem Soc, 137, pp.2832~2835 (2015)
30. Lee YG, "Use of a single CAR T cell and several bispecific adapters facilitates eradication of multiple antigenically different solid tumors", Cancer Res, 79, pp.387~396 (2019)
31. Newick K, "CAR T cell therapy for solid tumors", Annu Rev Med, 68, pp.139~152 (2017)
32. Jin MZ, "The updated landscape of tumor microenvironment and drug repurposing", Signal Transduct Target Ther, 5, pp.166~ (2020)
33. Craddock JA, "Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b", J Immunother, 33, pp.780~788 (2010)
34. Moon EK, "Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor", Clin Cancer Res, 17, pp.4719~4730 (2011)
35. Di Stasi A, "T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30have improved homing and antitumor activity in a Hodgkin tumor model", Blood, 113, pp.6392~6402 (2009)
36. Cadilha BL, "Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors", Sci Adv, 7, pp.eabi5781~ (2021)
37. Lesch S, "T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours", Nat Biomed Eng, 5, pp.1246~1260 (2021)
38. Caruana I, "Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes", Nat Med, 21, pp.524~529 (2015)
39. Chang ZL, "Rewiring T-cell responses to soluble factors with chimeric antigen receptors", Nat Chem Biol, 14, pp.317~324 (2018)
40. Tormoen GW, "Role of the immunosuppressive microenvironment in immunotherapy", Adv Radiat Oncol, 3, pp.520~526 (2018)
41. Leen AM, "Reversal of tumor immune inhibition using a chimeric cytokine receptor", Mol Ther, 22, pp.1211~1220 (2014)
42. Wilkie S, "Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4", J Biol Chem, 285, pp.25538~25544 (2010)
43. Ohta A, "A2A adenosine receptor protects tumors from antitumor T cells", Proc Natl Acad Sci U S A, 103, pp.13132~13137 (2006)
44. Zarek PE, "A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells", Blood, 111, pp.251~259 (2008)
45. Beavis PA, "Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy", J Clin Invest, 127, pp.929~941 (2017)
46. Geiger R, "L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity", Cell, 167, pp.829~842 (2016)
47. Bronte V, "Regulation of immune responses by L-arginine metabolism", Nat Rev Immunol, 5, pp.641~654 (2005)
48. Fultang L, "Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity", Blood, 136, pp.1155~1160 (2020)
49. Marasco M, "Molecular mechanism of SHP2 activation by PD-1 stimulation", Sci Adv, 6, pp.eaay4458~ (2020)
50. Seongju Jeong, "Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy", Immune Network, 20(1), pp.1~20 (2020), 대한면역학회[DOI]
51. Liu X, "A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors", Cancer Res, 76, pp.1578~1590 (2016)
52. Rupp LJ, "CRISPR", Cas9-mediated PD-1disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells, 2017, pp.7, 737~
53. Guo X, "Disruption of PD-1enhanced the anti-tumor activity of chimeric antigen receptor T cells against hepatocellular carcinoma", Front Pharmacol, 9, pp.1118~ (2018)
54. Hu B, "Nucleofection with plasmid DNA for CRISPR", Cas9-mediated inactivation of programmed cell death protein 1 in CD133-specific CAR T cells, 2019, pp.30, 446~458
55. Hu W, "CRISPR", Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions, 2019, pp.68, 365~377
56. Odorizzi PM, "Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells", J Exp Med, 212, pp.1125~1137 (2015)
57. Wartewig T, "PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis", Nature, 552, pp.121~125 (2017)
58. Lee YH, "PD-1and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells", Mol Ther, 30, pp.579~592 (2022)
59. Zou F, "Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56", Nat Commun, 10, pp.4109~ (2019)
60. Cherkassky L, "Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition", J Clin Invest, 126, pp.3130~3144 (2016)
61. Chen J, "NR4A transcription factors limit CAR T cell function in solid tumours", Nature, 567, pp.530~534 (2019)
62. Scott AC, "TOX is a critical regulator of tumour-specific T cell differentiation", Nature, 571, pp.270~274 (2019)
63. Khan O, "TOX transcriptionally and epigenetically programs CD8(+)T cell exhaustion", Nature, 571, pp.211~218 (2019)
64. Kim K, "Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer", Genome Med, 12, pp.22~ (2020)
65. Seo H, "TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8(+)T cell exhaustion(vol 116, pg 12410, 2019)", Proc Natl Acad Sci U S A, 116, pp.19761~19761 (2019)
66. Good CR, "Induction of T cell dysfunction and NK-like T cell differentiation in vitro and in patients after CAR T cell treatment", Cancer Res, 81(Suppl), pp.A60~ (2021)
67. Long AH, "4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors", Nat Med, 21, pp.581~590 (2015)
68. Murphy TL, "Specificity through cooperation : BATF-IRF interactions control immune-regulatory networks", Nat Rev Immunol, 13, pp.499~509 (2013)
69. Ghoneim HE, "De novo epigenetic programs inhibit PD-1 Blockade-mediated T cell rejuvenation", Cell, 170, pp.142~157 (2017)
70. Wang Y, "Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming", Nat Commun, 12, pp.409~ (2021)
71. Prinzing B, "Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity", Sci Transl Med, 13, pp.eabh0272~ (2021)
72. Weber EW, "Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling", Science, 372, pp.eaba1786~ (2021)
73. Pauken KE, "Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade", Science, 354, pp.1160~1165 (2016)
74. Deeks SG, "HIV infection", Nat Rev Dis Primers, 1, pp.15035~ (2015)
75. Maldini CR, "Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo", Nat Med, 26, pp.1776~1787 (2020)
76. Rust BJ, "Robust expansion of HIV CAR T cells following antigen boosting in ART-suppressed nonhuman primates", Blood, 136, pp.1722~1734 (2020)
77. Zhen A, "Long-term persistence and function of hematopoietic stem cell-derived chimeric antigen receptor T cells in a nonhuman primate model of HIV", AIDS, 2017, pp.13, e1006753~
78. Young LS, "Epstein-Barr virus : more than 50 years old and still providing surprises", Nat Rev Cancer, 16, pp.789~802 (2016)
79. Dragon AC, "CAR-T cells and TRUCKs that recognize an EBNA-3C-derived epitope presented on HLA-B*35 control Epstein-Barr virus-associated lymphoproliferation", J Immunother Cancer, 8, pp.e000736~ (2020)
80. Slabik C, "CAR-T cells targeting Epstein-Barr virus gp350 validated in a humanized mouse model of EBV infection and lymphoproliferative disease", Mol Ther Oncolytics, 18, pp.504~524 (2020)
81. Griffiths P, "Pathogenesis of human cytomegalovirus in the immunocompromised host", Nat Rev Microbiol, 19, pp.759~773 (2021)
82. Full F, "T cells engineered with a cytomegalovirus-specific chimeric immunoreceptor", J Virol, 84, pp.4083~4088 (2010)
83. Ali A, "Chimeric antigen receptors targeting human cytomegalovirus", J Infect Dis, 222, pp.853~862 (2020)
84. Brey CU, "A gB", CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells, 2018, pp.8, 17453~
85. Manns MP, "Hepatitis C virus infection", Nat Rev Dis Primers, 3, pp.17006~ (2017)
86. Sautto GA, "Chimeric antigen receptor(CAR)-engineered T cells redirected against hepatitis C virus(HCV)E2 glycoprotein", Gut, 65, pp.512~523 (2016)
87. Yuen MF, "Hepatitis B virus infection", Nat Rev Dis Primers, 4, pp.18035~ (2018)
88. Bohne F, "T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes", Gastroenterology, 134, pp.239~247 (2008)
89. Krebs K, "T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice", Gastroenterology, 145, pp.456~465 (2013)
90. Festag MM, "Evaluation of a fully human, hepatitis B virus-specific chimeric antigen receptor in an immunocompetent mouse model", Mol Ther, 27, pp.947~959 (2019)
91. Sette A, "Adaptive immunity to SARS-CoV-2 and COVID-19", Cell, 184, pp.861~880 (2021)
92. Guo X, "Effective chimeric antigen receptor T cells against SARS-CoV-2", iScience, 24, pp.103295~ (2021)
93. Depil S, "‘Off-the-shelf ’ allogeneic CAR T cells : development and challenges", Nat Rev Drug Discov, 19, pp.185~199 (2020)
94. van de Veerdonk FL, "Aspergillus fumigatus morphology and dynamic host interactions", Nat Rev Microbiol, 15, pp.661~674 (2017)
95. Kumaresan PR, "Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection", Proc Natl Acad Sci U S A, 111, pp.10660~10665 (2014)
96. Guo Q, "Rheumatoid arthritis : pathological mechanisms and modern pharmacologic therapies", Bone Res, 6, pp.15~ (2018)
97. Zhang B, "In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells", Ann Rheum Dis, 80, pp.176~184 (2021)
98. Hammers CM, "Mechanisms of disease : pemphigus and bullous pemphigoid", Annu Rev Pathol, 11, pp.175~197 (2016)
99. Ellebrecht CT, "Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease", Science, 353, pp.179~184 (2016)
100. Lee J, "Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris", J Clin Invest, 130, pp.6317~6324 (2020)
101. Kaul A, "Systemic lupus erythematosus", Nat Rev Dis Primers, 2, pp.16039~ (2016)
102. Kansal R, "Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus", Sci Transl Med, 11, pp.eaav1648~ (2019)
103. Jin X, "Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus", Cell Mol Immunol, 18, pp.1896~1903 (2021)
104. Mougiakakos D, "CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus", N Engl J Med, 385, pp.567~569 (2021)
105. Filippi M, "Multiple sclerosis", Nat Rev Dis Primers, 4, pp.43~ (2018)
106. Fransson M, "CAR", FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery, 2012, pp.9, 112~
107. De Paula Pohl A, "Engineered regulatory T cells expressing myelin-specific chimeric antigen receptors suppress EAE progression", Cell Immunol, 358, pp.104222~ (2020)
108. Frisoli ML, "Vitiligo : mechanisms of pathogenesis and treatment", Annu Rev Immunol, 38, pp.621~648 (2020)
109. Mukhatayev Z, "Antigen specificity enhances disease control by tregs in vitiligo", Front Immunol, 11, pp.581433~ (2020)
110. Aghajanian H, "Targeting cardiac fibrosis with engineered T cells", Nature, 573, pp.430~433 (2019)

관련 논문AI추천